Moderna Inc (MRNA) Is Not Likely To Be The Same Tomorrow

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

Moderna Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Moderna Inc is $46.81B. A total of 3.94 million shares were traded on the day, compared to an average of 3.93M shares.

In the most recent transaction, AFEYAN NOUBAR sold 15,000 shares of MRNA for 110.92 per share on May 01 ’24. After the transaction, the Director now owns 2,026,931 company shares. In a previous transaction on Apr 24 ’24, AFEYAN NOUBAR sold 15,000 shares at 108.32 per share. MRNA shares that Director owns now total 2,041,931.

Among the insiders who sold shares, AFEYAN NOUBAR disposed of 15,000 shares on Apr 17 ’24 at a per-share price of $103.38. This resulted in the Director holding 2,056,931 shares of MRNA after the transaction. In another insider transaction, Hoge Stephen sold 15,000 shares at $105.02 per share on Apr 15 ’24. Company shares held by the President now total 1,486,241.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, MRNA has a high of $142.79 and a low of $62.55.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. MRNA’s latest balance sheet shows that the firm has $10.73B in Cash & Short Term Investments as of fiscal 2021. There were $916.00M in debt and $9.13B in liabilities at the time. Its Book Value Per Share was $33.46, while its Total Shareholder’s Equity was $14.14B.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRNA is Buy with a score of 3.65.

Most Popular

Related Posts